Bimekizumab

Active substance
Bimekizumab
Domain
Chronic immune diseases
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Skin diseases
Extended indication
Psoriasis

1. Product

Manufacturer
UCB
Mechanism of action
Interleukin inhibitor
Route of administration
Subcutaneous
Therapeutical formulation
Injection
Budgetting framework
Intermural (MSZ)
Additional comments
Bimekizumab is a novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. Vermoedelijk intramurale bekostiging vanwege het feit dat het een biological is.

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Normal trajectory
Submission date
July 2020
Expected Registration
August 2021
Orphan drug
No
Registration phase
Clinical trials

3. Therapeutic value

Current treatment options
Brodalumab, Ixekizumab, Secukinumab, Ustekinumab
Therapeutic value
No judgement
References
Papp et al. JAM ACAD DERMATOL 2018; 79: 277-286.

4. Expected patient volume per year

Patient volume

350

Market share is generally not included unless otherwise stated.

Additional comments
Komt in principe beschikbaar voor alle patiënten met matige tot ernstige psoriasis, in Nederland zijn dat er ca. 165.000. Middel zal zijn plek moeten veroveren ten opzichte van andere reeds aanwezige biologicals. Verwachting is een paar honderd patiënten. Aantallen afhankelijk van toekomstig label.

5. Expected cost per patient per year

Cost
15,000 - 20,000
References
Medicijnkosten.nl; Farmacotherapeutisch Kompas
Additional comments
Prijs gebaseerd op inschattingen van andere biologicals met dezelfde indicatie (Brodalumab, Ixekizumab, Secukinumab, Ustekinumab).

6. Potential total cost per year

Total cost

6,125,000

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

7. Off label use

Off label use
No

8. Indication extension

Indication extension
Yes
Indication extensions
Psoriatis arthritis; Ankylosing spondylitis
References
UCB pipeline

9. Other information

There is currently no futher information available.